Skip to main content
icon for 特朗普将宣布谁将担任下一任FDA专员?

特朗普将宣布谁将担任下一任FDA专员?

icon for 特朗普将宣布谁将担任下一任FDA专员?

特朗普将宣布谁将担任下一任FDA专员?

Kyle Diamantas 54%

No announcement by December 31 15.2%

Stephen Hahn 4%

Brett Giroir 3.9%

Polymarket
最新

Kyle Diamantas 54%

No announcement by December 31 15.2%

Stephen Hahn 4%

Brett Giroir 3.9%

Polymarket
最新

Kyle Diamantas

$1,525 交易量

54%

Stephen Hahn

$976 交易量

4%

Brett Giroir

$1,510 交易量

4%

Grace Graham

$1,893 交易量

3%

Sara Brenner

$849 交易量

3%

No announcement by December 31

$533 交易量

15%

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s resignation has positioned the FDA deputy commissioner for food as the clear frontrunner in trader assessments for the permanent role. Diamantas assumed acting duties in mid-May 2026 after serving in senior FDA food-policy positions and has received public White House support for advancing administration priorities on food safety and regulatory reform. Other names under active consideration, including former commissioner Stephen Hahn and former acting commissioner Brett Giroir, register lower probabilities consistent with their more limited recent involvement in day-to-day agency operations. The market also prices a meaningful chance of no formal announcement before year-end, reflecting the ongoing search process and typical timelines for Senate-confirmed appointments.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$7,286
结束日期
2026-12-31
市场开放时间
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s resignation has positioned the FDA deputy commissioner for food as the clear frontrunner in trader assessments for the permanent role. Diamantas assumed acting duties in mid-May 2026 after serving in senior FDA food-policy positions and has received public White House support for advancing administration priorities on food safety and regulatory reform. Other names under active consideration, including former commissioner Stephen Hahn and former acting commissioner Brett Giroir, register lower probabilities consistent with their more limited recent involvement in day-to-day agency operations. The market also prices a meaningful chance of no formal announcement before year-end, reflecting the ongoing search process and typical timelines for Senate-confirmed appointments.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$7,286
结束日期
2026-12-31
市场开放时间
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.

警惕外部链接哦。

常见问题

"特朗普将宣布谁将担任下一任FDA专员?"是 Polymarket 上一个拥有 6 个可能结果的预测市场,交易者根据自己的判断买卖份额。当前领先结果为"Kyle Diamantas",概率为 54%,其次是"No announcement by December 31",概率为 15%。价格反映社区的实时概率。例如,价格为 54¢ 的份额意味着市场集体认为该结果的概率为 54%。这些赔率会随着交易者的反应而不断变化。正确结果的份额在市场结算时可兑换为每份 $1。

"特朗普将宣布谁将担任下一任FDA专员?"是 Polymarket 上新创建的市场,于May 13, 2026上线。作为一个新市场,这是你率先设定赔率并建立初始价格信号的机会。你也可以将本页加入书签,以便跟踪交易量和活动。

要在"特朗普将宣布谁将担任下一任FDA专员?"上交易,浏览本页上列出的 6 个可用结果。每个结果显示一个代表市场隐含概率的当前价格。要建仓,选择你认为最可能的结果,选择"是"支持或"否"反对,输入金额并点击"交易"。如果你选择的结果在市场结算时正确,你的"是"份额每份支付 $1。如果不正确,支付 $0。你也可以在结算前随时卖出份额。

"特朗普将宣布谁将担任下一任FDA专员?"的当前领先者是"Kyle Diamantas",概率为 54%,意味着市场对该结果的概率评估为 54%。紧随其后的结果是"No announcement by December 31",概率为 15%。这些赔率随着交易者买卖份额而实时更新。请经常回来查看或将本页加入书签。

"特朗普将宣布谁将担任下一任FDA专员?"的结算规则明确定义了每个结果被宣布为获胜者所需满足的条件——包括用于确定结果的官方数据来源。你可以在本页评论上方的"规则"部分查看完整的结算标准。我们建议在交易前仔细阅读规则,因为它们规定了精确的条件、特殊情况和数据来源。